Fosamax Osteonecrosis of the Jaw Attorney: Georgia Fosamax Osteonecrosis of the Jaw Injury Lawyer

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Targeted Risk Awareness

For decades, general health and science communication has served as a foundational pillar for public understanding, offering broad guidance on wellness, disease prevention, and the safe use of medications. This legacy context has traditionally emphasized the benefits of pharmaceutical interventions, often framing them within a narrative of improved quality of life and long-term health management. Within this framework, medications like bisphosphonates were introduced as effective tools for managing bone density disorders, with public discourse focusing primarily on their therapeutic advantages. As the landscape of health information evolves, a more nuanced perspective has emerged, one that acknowledges the complex interplay between medication use and unintended physiological outcomes. This shift requires moving beyond general wellness narratives to consider specific, real-world consequences that may arise from prolonged exposure to certain compounds. In particular, the transition from broad health education to targeted risk awareness becomes critical when examining the potential implications of sustained bisphosphonate therapy.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication prescribed for the treatment of osteoporosis and other bone diseases. A known adverse effect associated with its use is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. This section reviews the clinical presentation, pharmacological background, mechanistic pathways, and risk considerations for patients who may have been affected. Osteonecrosis of the jaw presents as exposed bone in the oral cavity that persists for more than eight weeks without evidence of healing. The condition can occur spontaneously but is often associated with dental procedures such as tooth extraction, dental implants, or boney surgery, as well as local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors include invasive dental procedures, diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Diagnosis is primarily clinical, supported by imaging and exclusion of other causes. Multiscale characterization of jawbone tissue is helping researchers better understand the unique responses of the jaw to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Pharmacology and Reported Adverse Effects of Fosamax

Fosamax (alendronate) belongs to the bisphosphonate class of drugs, which inhibit osteoclast-mediated bone resorption. While effective for osteoporosis, bisphosphonates have been associated with adverse effects including ONJ. In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as bone pain or jaw symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, post-marketing reports have documented ONJ in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experienced relief of symptoms after stopping the medication, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The exact mechanism by which bisphosphonates contribute to ONJ is not fully understood, but several pathways are proposed. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress osteoclast activity. This suppression may impair normal bone remodeling and healing after dental procedures or microtrauma. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone. The presence of local infection or inflammation can further compromise tissue viability. Multiscale characterization of jawbone tissue is providing comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). While most published literature on ONJ is in humans, a retrospective case series in cats also highlights the condition, noting that it is rare in that species but shares similar features (https://pubmed.ncbi.nlm.nih.gov/39247125/).

Risk Considerations and Legal Context for Affected Patients

The prescribing information for Fosamax includes a warning about ONJ, stating that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning notes that ONJ can occur spontaneously or after dental procedures and that risk may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the adequacy of these warnings in clinical practice may be questioned, as some patients and healthcare providers may not be fully aware of the risk, particularly in the context of routine dental care. Patients who develop ONJ after taking Fosamax may consider legal options. A survey of specialists found that 56% of physicians had not encountered any cases of medication-related ONJ in the past year, while 44% had encountered between one and four cases (https://pubmed.ncbi.nlm.nih.gov/40604825/). When encountering patients with osteonecrosis, 39.2% of specialists most frequently referred them to oral and maxillofacial surgery (https://pubmed.ncbi.nlm.nih.gov/40604825/). The group that most frequently requested consultations regarding bisphosphonates was dentists (50.4%), followed by oral and maxillofacial surgeons (36.8%) (https://pubmed.ncbi.nlm.nih.gov/40604825/). This suggests that dental professionals are often the first to identify potential ONJ cases. Patients seeking legal representation should document their medical history, including the timeline of Fosamax use, any dental procedures, and the onset of jaw symptoms. An attorney can help evaluate whether the manufacturer provided adequate warnings and whether the patient’s injury is linked to the medication. The time to onset of ONJ symptoms after starting Fosamax can vary widely, from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In some cases, symptoms may not appear until after a dental procedure or local infection. The risk of ONJ may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who have taken Fosamax for several years may be at higher risk, especially if they undergo invasive dental procedures. Discontinuation of the drug may reduce the risk, but ONJ can still occur after stopping treatment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis. It has been associated with osteonecrosis of the jaw (ONJ), a condition where the jawbone becomes exposed and fails to heal. The risk may increase with longer duration of use, especially after dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What are the symptoms of osteonecrosis of the jaw?

Symptoms include exposed bone in the mouth that persists for more than eight weeks, pain, swelling, infection, and loose teeth. It often occurs after dental procedures like tooth extraction (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How long after taking Fosamax can osteonecrosis of the jaw develop?

The time to onset can vary from one day to several months after starting the drug. In some cases, symptoms may not appear until after a dental procedure or infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What should I do if I think I have osteonecrosis of the jaw from Fosamax?

You should consult your healthcare provider and a dental specialist. Document your medical history, including Fosamax use and any dental procedures. You may also consider contacting an attorney to evaluate your legal options regarding inadequate warnings (https://pubmed.ncbi.nlm.nih.gov/40604825/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.